Milestone is a drug development company developing novel small molecule therapeutics based on clinically validated mechanisms for cardiovascular diseases. Milestone’s lead product is a novel and potent short-acting calcium channel antagonist for the systemic treatment of transient cardiovascular conditions such as atrial arrhythmias and angina.
Milestone Pharma is a BDC Capital Healthcare Venture Fund company, co-managed in partnership by Amplitude Venture Capital.
Dion Madsen, Founding partner at Amplitude Venture Capital.
Milestone Pharmaceuticals Closes $55 Million Series C FinancingLearn More
Milestone Pharmaceuticals Closes US$17 Million Series B Financing to Complete Phase 2 Clinical Studies for MSP-2017Learn More
Milestone Pharmaceuticals Announces USAN Approval of Generic Name "Etripamil" for its Phase 2 Clinical Development Product for the Treatment of Paroxysmal Supraventricular TachycardiaLearn More
Certain news link to external sites and are presented in French only.